Related Experiment Video

Updated: Aug 7, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Decreased lung cancer survival with hormone-replacement therapy: caused by a decreased tissue factor pathway

Helene F S Negaard, Anette L Eilertsen, Anders Dahm

    Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
    |June 10, 2006
    PubMed
    Abstract

    No abstract available in PubMed .

    Related Experiment Videos

    Last Updated: Aug 7, 2026

    An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
    06:18

    An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

    Published on: August 13, 2019

    Related Concept Videos

    Cancer Therapies02:49

    Cancer Therapies

    Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
    However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

    Articles linked to this work by shared authors, journal, and citation graph.

    SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma.

    British journal of haematology·2026

    Deterioration in Physical Fitness and Changes in Body Composition After Cisplatin-Based Chemotherapy for Metastatic Testicular Cancer.

    Clinical genitourinary cancer·2026

    Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma.

    Blood cancer journal·2025

    High-dose chemotherapy in male germ cell cancer patients-a study by the SWENOTECA group.

    British journal of cancer·2025

    Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year update.

    Blood advances·2025

    Inpatient and postdischarge mortality among children with anaemia and malaria parasitaemia in Kenya: a cohort study.

    BMJ global health·2024

    Five-Year Follow-Up of the Phase III ASCOT Trial of Adjuvant S-1 After Resection for Biliary Tract Cancer.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    When Survival Separates.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Transcriptomic Plasticity and Its Spatial Architecture Shape Melanoma Response to Immunotherapy and Its Combination With BRAF/MEKi.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Patient-Level Evaluation of Optimal Margin Width for Lumpectomy in Ductal Carcinoma In Situ: An Analysis of Patients in the National Cancer Database Special Study.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Association Between Patient-Reported Outcomes and Health Care Resource Utilization: Toward Developing Patient-Centered Value Measures in Cancer Care.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Mindfulness and Tai Chi for Sleep, Fatigue, and Pain in Distressed People After Cancer Treatment: A Partially Randomized Patient-Preference Comparative Effectiveness Trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Long-Term Efficacy and Allograft Loss after Immune Checkpoint Inhibitor Therapy in Solid Organ Transplant Recipients with Advanced Cutaneous Squamous Cell Carcinoma.

    medRxiv : the preprint server for health sciences·2026

    Engineered subtilisin protease degrades active KRAS in cancer cells leading to differential cell targeting.

    Research square·2026

    Microenvironment-derived acetylated amino acids promote glioblastoma treatment resistance.

    Research square·2026

    The therapy-conditioned host: a state-transition framework for second primary cancer evolution.

    Frontiers in oncology·2026

    Cyclopeptide 161 protects human dermal fibroblasts against UV-induced damage via the MEK1/2-ERK1/2 signaling pathway.

    Frontiers in physiology·2026

    Dynamic clonal evolution of multiple bypass resistance mechanisms in EGFR-mutant lung adenocarcinoma: a case report.

    Frontiers in oncology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us